Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation.
cytopenia
eltrombopag
haematopoietic stem cell transplantation
poor graft function
Journal
Therapeutic advances in hematology
ISSN: 2040-6207
Titre abrégé: Ther Adv Hematol
Pays: England
ID NLM: 101549589
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
06
2020
accepted:
07
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
Patients with post-transplant cytopenias due to poor graft function or primary engraftment failure show poor prognosis with a high mortality rate mainly because of graft In the present study patients with primary engraftment failure ( In 10/12 patients eltrombopag significantly enhanced blood count values and patients became transfusion independent. Once stable haematological response was obtained, treatment was tapered until final discontinuation in 9/10 responding patients. No grade 3 or 4 toxicities were observed. At time of last follow up, 3/12 patients were dead, 2 due to disease relapse, 1 due to GVHD and pneumonia. All patients except one maintained their complete response and remain transfusion independent at a median of 858 (range: 429-1119) days. These preliminary data confirm that eltrombopag is able to rescue multilineage haematopoiesis in patients with treatment-refractory cytopenias after allogeneic HSCT.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with post-transplant cytopenias due to poor graft function or primary engraftment failure show poor prognosis with a high mortality rate mainly because of graft
METHODS
METHODS
In the present study patients with primary engraftment failure (
RESULTS
RESULTS
In 10/12 patients eltrombopag significantly enhanced blood count values and patients became transfusion independent. Once stable haematological response was obtained, treatment was tapered until final discontinuation in 9/10 responding patients. No grade 3 or 4 toxicities were observed. At time of last follow up, 3/12 patients were dead, 2 due to disease relapse, 1 due to GVHD and pneumonia. All patients except one maintained their complete response and remain transfusion independent at a median of 858 (range: 429-1119) days.
CONCLUSION
CONCLUSIONS
These preliminary data confirm that eltrombopag is able to rescue multilineage haematopoiesis in patients with treatment-refractory cytopenias after allogeneic HSCT.
Identifiants
pubmed: 33194161
doi: 10.1177/2040620720961910
pii: 10.1177_2040620720961910
pmc: PMC7594218
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040620720961910Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: AB has been a speaker for Novartis.
Références
Biol Blood Marrow Transplant. 2016 May;22(5):919-24
pubmed: 26785333
Br J Haematol. 2017 Jan;176(1):101-110
pubmed: 27734464
Haematologica. 2013 Jul;98(7):1045-8
pubmed: 23585526
Pediatr Transplant. 1999;3 Suppl 1:35-40
pubmed: 10587969
J Clin Invest. 2008 Aug;118(8):2832-44
pubmed: 18618018
Biol Blood Marrow Transplant. 2017 Jul;23(7):1072-1077
pubmed: 28323004
Biol Blood Marrow Transplant. 2018 Aug;24(8):1765-1770
pubmed: 29684566
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Bone Marrow Transplant. 2019 Aug;54(8):1310-1318
pubmed: 30664724
Oncotarget. 2016 May 24;7(21):30892-906
pubmed: 27105530
Bone Marrow Transplant. 2019 Aug;54(8):1346-1353
pubmed: 30679824
Biol Blood Marrow Transplant. 2020 Mar;26(3):e65-e73
pubmed: 31830528
Stem Cell Res. 2012 Sep;9(2):77-86
pubmed: 22683680
Blood. 1995 Oct 1;86(7):2516-25
pubmed: 7545460
Blood. 1997 May 15;89(10):3691-9
pubmed: 9160674
J Immunol. 1997 Jun 1;158(11):5169-77
pubmed: 9164933
Int J Hematol. 2012 Feb;95(2):149-59
pubmed: 22193844
Bone Marrow Transplant. 2014 Apr;49(4):585-7
pubmed: 24419518
Blood. 1995 Jun 15;85(12):3444-51
pubmed: 7780132
N Engl J Med. 2007 Nov 29;357(22):2227-36
pubmed: 18046027
Blood. 2014 Mar 20;123(12):1818-25
pubmed: 24345753
Bone Marrow Res. 2012;2012:270425
pubmed: 22900188
Bone Marrow Transplant. 2013 Apr;48(4):537-43
pubmed: 23222384
Bone Marrow Transplant. 2004 Apr;33(7):729-34
pubmed: 14755315
Cell Transplant. 2014;23(9):1087-98
pubmed: 23294601
Haematologica. 2006 Jul;91(7):935-40
pubmed: 16818281
Biol Blood Marrow Transplant. 2019 Jul;25(7):1320-1324
pubmed: 30710685
Leuk Lymphoma. 2016;57(4):965-8
pubmed: 26402469
J Cell Biochem. 2011 Jun;112(6):1491-8
pubmed: 21360575
Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87
pubmed: 15737890
Cell Stem Cell. 2007 Dec 13;1(6):671-84
pubmed: 18371408
Blood. 1996 Mar 15;87(6):2162-70
pubmed: 8630375
N Engl J Med. 2007 Nov 29;357(22):2237-47
pubmed: 18046028
J Hematol Oncol. 2018 Aug 16;11(1):103
pubmed: 30115080
Blood. 1994 Dec 15;84(12):4045-52
pubmed: 7527664